28-day Repeated-dose Study of SCO-240

An Open label, Single-Center, Phase 1 Study to Investigate the Safety and Pharmacodynamics of Multiple Doses of SCO-240 in Healthy Adult Subjects - 28-day Repeated-dose Study of SCO-240

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031250659

Enrollment

Registered

2026-01-20

Start date

2026-02-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric growth hormone deficiency

Interventions

Administer SCO-240 1 mg or 10 mg once daily for 28 days

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: - Gender: Male - At the time of informed consent, subjects in young adult group are aged >=18 and =65 and =50 kg, body mass index (BMI) >=18.5 kg/m2 and =<25.0 kg/m2

Exclusion criteria

Exclusion criteria: - Subjects who have a present illness such as cardiovascular disease, central nervous system disease, gastrointestinal disease, hematopoietic disease, renal failure, metabolic or endocrine disorder, serious allergy, asthma, hypoxemia, hypertension, convulsion or allergic rash. For older adult group, conditions with mild severity and no anticipated changes in medications are acceptable.

Design outcomes

Primary

Measure	Time frame
Safety, Tolerability, and Pharmacodynamic	—

Contacts

Public ContactHarunobu Nishizaki

SCOHIA PHARMA, Inc.

harunobu.nishizaki@scohia.com+81-466-27-3205

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026